

Not for release to US wire services or distribution in the United States

Share purchase plan completed

Sydney, Australia – Thursday, 17 September 2026 – **Radiopharm Theranostics Limited** (ASX:RAD; Nasdaq:RADX), a developer of a world-class platform of radiopharmaceutical products for both diagnostic and therapeutic uses, announced a share purchase plan (**SPP**) on 24 July 2026, followed by lodgement of a Prospectus dated 30 July 2026, and the SPP closed on 10 September 2026.

The SPP raised approximately A\$3.0 million, comprising approximately A\$1.4 million subscribed by shareholders, ~A\$0.1 million subscribed by participating Directors, and ~A\$1.5 million subscribed by Trading Capital Management (HK) Ltd pursuant to a shortfall commitment (Shortfall Investor). This brings the total capital raised, including the placement announced on 24 July 2026, to ~A\$15.5 million.

The issue of SPP Shares and SPP Attaching Options was approved by shareholders at a General Meeting held on 11 September 2026. The SPP Shares will be issued at \$0.009 ea. in accordance with the terms of the Prospectus. The SPP Attaching Options will have an exercise price of A\$0.018 per option with an expiry date of 31 July 2029. The full terms of the SPP Attaching Options are annexed to the announcement on 24 July 2026.

333,333,299 SPP Shares and 333,333,299 SPP Attaching Options are scheduled to be issued on Thursday, 17 September 2026 to SPP participants and the Shortfall Investor. The Company has applied to ASX for the SPP Attaching Options to be quoted on the ASX.

The Company would like to thank shareholders who supported the SPP.

Key dates

Event	Date (2026)
Settlement of Tranche 2 Placement Shares	Wednesday, 16 September
Allotment of Tranche 2 Placement Shares and Attaching Options, SPP Shares and SPP Attaching Options	Thursday, 17 September

The Company reserves the right to amend the above timetable, at its discretion, including for the purposes of any Australian Securities and Investments Commission (**ASIC**) and ASX requirements.

Authorised on behalf of the Radiopharm Theranostics board of directors by Executive Chairman Paul Hopper.

ASX ANNOUNCEMENT
17 September 2026

For more information:

Riccardo Canevari
CEO & Managing Director
P: +1 862 309 0293
E: rc@radiopharmtheranostics.com

Paul Hopper
Executive Chairman
E: paulhopper@lifescienceportfolio.com

Matt Wright
NWR Communications
P: +61 451 896 420
E: matt@nwrcommunications.com.au

Follow Radiopharm Theranostics:

Website – <https://radiopharmtheranostics.com/>

Twitter – <https://twitter.com/TeamRadiopharm>

Linked In – <https://www.linkedin.com/company/radiopharm-theranostics/>

Not an offer of securities

This announcement has been prepared for publication in Australia and may not be released to US wire services or distributed in the United States. This announcement does not constitute an offer to sell, or a solicitation of an offer to buy, securities in the United States or any other jurisdiction. Any securities described in this announcement have not been registered under the US Securities Act of 1933 and may not be offered or sold in the United States except in transactions exempt from, or not subject to, the registration requirements of the US Securities Act and applicable US state securities laws.

Forward-looking statements

This announcement contains certain 'forward-looking statements' within the meaning of the securities laws of applicable jurisdictions. Forward-looking statements can generally be identified by the use of forward-looking words such as 'may,' 'should,' 'expect,' 'anticipate,' 'estimate,' 'scheduled' or 'continue' or the negative version of them or comparable terminology. Any forecasts or other forward-looking statements contained in this announcement are subject to known and unknown risks and uncertainties and may involve significant elements of subjective judgment and assumptions as to future events which may or may not be correct. There are usually differences between forecast and actual results because events and actual circumstances frequently do not occur as forecast and these differences may be material. Radiopharm does not give any representation, assurance or guarantee that the occurrence of the events expressed or implied in any forward-looking statements in this announcement will actually occur and you are cautioned not to place undue reliance on forward-looking statements.